NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong reminds investors of an investigation concerning whether Sinovac Biotech Ltd (NASDAQ: SVA) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/SVA-Info-Request-Form-1640 There is no cost or obligation to you.
On December 21, 2016, an article published by SeekingAlpha.com revealed that Sinovac's Chairman and Chief Executive Officer, Weidong Yin, paid bribes to the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration and his wife, to help advance drug applications and evaluations. Sinovac later announced on May 16, 2017 that the Securities Exchange Commission is investigating the Company for alleged bribery mentioned in SeekingAlpha's article, and that Sinovac would not be able to file its annual financial results on time.
To learn more about the investigation of Sinovac Biotech Ltd., contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/SVA-Info-Request-Form-1640
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.